Growth Factor News and Research

RSS

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein, researchers from The University of Texas MD Anderson Cancer Center report in the Nov. 16 edition of Cancer Cell.

16 Nov 2010

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Threshold Pharmaceuticals, Inc. today announced clinical trial results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The results were presented at the 16th Annual Connective Tissue Oncology Society (CTOS) Meeting taking place in Paris, France from November 11 to 13, 2010.

12 Nov 2010

Researchers study Rett neurons in a Petri dish

A collaborative effort between researchers at the Salk Institute for Biological Studies and the University of California, San Diego, successfully used human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome to replicate autism in the lab and study the molecular pathogenesis of the disease.

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

Scientists create functional neurons to study ASD development

Using induced pluripotent stem cells from patients with Rett syndrome, scientists at the University of California, San Diego School of Medicine have created functional neurons that provide the first human cellular model for studying the development of autism spectrum disorder (ASD) and could be used as a tool for drug screening, diagnosis and personalized treatment.

12 Nov 2010

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

Agenta Biotechnologies, Inc., a private biotechnology company, announced that it has received a $1.1 million grant from the National Institutes of Health and National Institute of Dental and Craniofacial Research (NIH/NIDCR) for the further development of a biologically activated membrane to improve soft tissue healing associated with oral surgery.

12 Nov 2010

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

NephRx Corporation today announced that it has initiated a Phase I clinical trial of its lead compound NX001 and has successfully dosed the first subject in the study. NX001, a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure, is in development for the prevention of delayed graft function (DGF) in kidney transplantation patients.

11 Nov 2010

New stem cell gene, enzyme replacement treatment for Tay-Sachs disease

StemCellRegenMed, Inc. announces that a new stem cell gene and enzyme replacement treatment has been performed on a fourteen month old child with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a devastating disease that afflicts children primarily of parents of Jewish heritage and in very rare cases families of Eastern European background and the Cajun region in the U.S.A.

10 Nov 2010

Lung cancer in smokers versus non-smokers shows different genetic mutations

A group of scientists at B.C. Cancer Agency have found that lung cancers in smokers have different genetic mutations and look different than lung cancer in non-smokers. According to senior scientist at the BC Cancer Agency Research Centre Wan Lam, this finding is significant because it means that from now on, research, treatments and diagnostics should be tailored to the distinct genetic variations in the different lung cancers instead of expecting that a one-size fits all approach will work. He said, “At the current time, treatment does not distinguish between these different types. The subtypes are all grouped together. But with this work, we are beginning to tease out the subtypes.” The study was presented Tuesday at a conference in Philadelphia of the American Association of Cancer Research.

10 Nov 2010

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that it has received approval for its real-time PCR-based Epidermal Growth Factor Receptor Assay (the "EGFR PCR Assay") for the use of lung cancer targeted drugs from the State Food and Drug Administration of China (the "SFDA").

10 Nov 2010

Study finds different DNA alterations in tumor genomes of smokers and never-smokers

Lung tumors in those who smoke and those who never smoked have different DNA alterations in the tumor genomes, according to results of a pilot study presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, will be presented during the 22nd Annual Symposium of EORTC-NCI-AACR being held November 16-19, 2010 in Berlin, Germany.

10 Nov 2010

Low levels of growth hormone may contribute to growth defects in cystic fibrosis

A new study using a pig model of cystic fibrosis (CF) suggests that low levels of a growth promoting hormone at or before birth may contribute to growth defects in patients with CF.

10 Nov 2010

Fibroblast growth factor-2 stimulates periodontal regeneration: Study

It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.

10 Nov 2010

ArQule reduces third quarter net loss to $6,394,000

ArQule, Inc. today reported its results of operations for the fiscal quarter and nine months ended September 30, 2010.

9 Nov 2010

Study discovers role of Vav1 oncogene in several cancers

Researchers at the Hebrew University of Jerusalem have discovered that Vav1 - an oncogene (cancer-causing gene) found in recent years to be one of the factors in tumorous tissue growth -- plays a wider role in several types of cancer than had previously been thought. The discovery has implications for further concentration on targeting this gene in cancer research.

9 Nov 2010

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.

8 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

Growth Factor News and Research

Study: EGFR inhibtion may help treat triple negative breast cancer

RBC boosting drugs may undermine breast cancer treatment with Herceptin

Clinical trial results of Threshold's TH-302 hypoxia-activated prodrug presented at 16th CTOS annual meeting

Researchers study Rett neurons in a Petri dish

Scientists unveil mechanism of liver regeneration

Scientists create functional neurons to study ASD development

NIH/NIDCR awards $1.1 million grant to Agenta for soft tissue healing development

NephRx initiates NX001 Phase I clinical trial to prevent DGF in kidney transplant patients

New stem cell gene, enzyme replacement treatment for Tay-Sachs disease

Lung cancer in smokers versus non-smokers shows different genetic mutations

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

Study finds different DNA alterations in tumor genomes of smokers and never-smokers

Data from AVEO's tivozanib-FOLFOX6 combination Phase 1b trial presented at 22nd EORTC-NCI-AACR

Low levels of growth hormone may contribute to growth defects in cystic fibrosis

Fibroblast growth factor-2 stimulates periodontal regeneration: Study

ArQule reduces third quarter net loss to $6,394,000

Study discovers role of Vav1 oncogene in several cancers

New COLD-PCR technology to detect EGFR gene mutation

Raptor initiates dosing in DR Cysteamine Phase 2 clinical trial for Huntington's Disease

Potential new biomarkers for very early prostate cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News